nach oben

American Journal of Cardiovascular Drugs

Erschienen in:

01.08.2013 | Current Opinion

Inhibition of Atherosclerosis by Angiotensin II Type 1 Receptor Antagonists

verfasst von: Stefan Peters

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Excerpt

It has been suggested that angiotensin II type 1 receptor (AT1) antagonists (angiotensin receptor blockers [ARBs]) can inhibit atherosclerosis by one or more of the following mechanisms: reduction of inflammation [1], low density lipoprotein (LDL) oxidation [2], activation of neutrophils [3], bradykinin activation [4], angiotensin II type 2 receptor activation [5], and apoptosis of smooth muscle cells [6]. …

Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372–8.PubMedCrossRef

Seeger H, Mueck AO, Lippert TH. Effects of valsartan and 17-beta-estradiol on the oxidation of low-density lipoprotein in vitro. Coron Artery Dis. 2000;11:347–9.PubMedCrossRef

Raiden S, Giordano M, Andonegui G, et al. Losartan, s selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formyl-methionyl-leucyl-phenylalanine to neutrophil receptors. J Pharmacol Exp Ther. 1997;281:624–8.PubMed

Hornig B, Köhler C, Schlink D, et al. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B1-dependent mechanism. Hypertension. 2003;41:1092–6.PubMedCrossRef

Volpe M, Paolis P. Angiotensin II AT” subtype receptors: an emerging target for cardiovascular therapy. Ital Heart J. 2000;1:96–103.PubMed

Ono H, Ishimitsu T. Effects of angiotensin II type 1 and 2 receptor on apoptosis. Nippon Rinsho. 2002;60:1887–92.PubMed

Yau L, Wilson DP, Werner JP, et al. Bradykinin receptor antagonists attenuate neointimal proliferation postangioplasty. Am J Physiol Heart Circ Physiol. 2001;261:1648–56.

Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010;55:976–82.PubMedCrossRef

Hirohata A, Yamamoto K, Miyoshi T, et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis. 2012;220:134–8.PubMedCrossRef

10.

Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5:301–14.PubMedCrossRef

11.

Iwai M, Nakaoka H, Senba I, et al. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II type 1 receptor blockade on vascular remodelling. Hypertension. 2012;60:137–44.PubMedCrossRef

12.

Guerin P, Sauzeau V, Rolli-Derkinderen M, et al. Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin. J Vasc Res. 2005;42:21–8.PubMedCrossRef

13.

Cohn JN, Anand IS, Latini R, Valsartan Heart Failure Trial Investigators, et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003;108:1306–9.PubMedCrossRef

14.

Amano T, Matsubara T, Izana H, et al. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol. 2006;97:785–8.PubMedCrossRef

15.

McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study. Circulation. 1999;100:1056–64.PubMedCrossRef

16.

Okada T, Yamamoto H, Okimoto T, et al. Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents. Circ J. 2011;75:1641–8.PubMedCrossRef

17.

Okumura M, Iwai M, Ide A, et al. Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression. Hypertension. 2005;46:577–83.PubMedCrossRef

18.

Matsuo Y, Imanishi T, Hayashi Y, et al. The effect of senescence of endothelial progenitor cells on in-stent restenosis in patients undergoing coronary stenting. Intern Med. 2006;45:581–7.PubMedCrossRef

19.

Bahlmann FH, de Groot K, Mueller O, et al. Stimulation of endothelial progenitor cells. A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005;45:526–9.PubMedCrossRef

20.

Nickenig G, Baumer AT, Grohe C, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998;97:2197–201.PubMedCrossRef

21.

Anand IS, Latini R, Florea VG, for the Val-HeFT Investigators, et al. C-reactive protein in heart failure, prognostic value and the effect of valsartan. Circulation. 2005;112:1428–34.PubMedCrossRef

22.

Ridker PM, Danielson E, Rifai N, Val-MARC Investigators, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:73–9.PubMedCrossRef

23.

Krämer J, Ruf RG, Schmidt S, et al. The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial – a multicenter study of AT1-receptor blocker therapy in coronary stenting. J Invasive Cardiol. 2008;20:205–10.PubMed

24.

Yokoyama J, Higuma T, Tomita H, et al. Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. Int J Cardiol. 2009;132:114–20.PubMedCrossRef

25.

Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.PubMedCrossRef

26.

Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–8.PubMedCrossRef

27.

Yusuf S, Teo KK, Pogue J, for the ONTARGET Investigators, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.PubMedCrossRef

28.

Kun X, Yong L, Bo J, et al. Neointimal hyperplasia inhibition effect of angiotensin II type 1 receptor blockers in patients after coronary stent implantation: a meta-analysis. Am J Cardiovasc Drugs. 2011;11:209–13.PubMedCrossRef

29.

Peters S, Koehler B, Steffen H, et al. Late lumen loss and follow-up diameter stenosis at different doses of oral valsartan six months after bare-metal stent implantation in type B2/C coronary lesions. Int J Cardiol. 2010;142:29–32.PubMedCrossRef

30.

Peters S. Comparison of efficacy of low- (80 mg/d) and high- (160–320 mg/d) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Am J Cardiovasc Drugs. 2008;8:83–7.PubMedCrossRef

31.

Peters S, Trümmel M, Meyners W, et al. Valsartan versus ACE inhibition after bare metal stent implantation – results of the VALVACE trial. Int J Cardiol. 2005;98:331–5.PubMedCrossRef

32.

Peters S, Götting B, Trümmel M, et al. Valsartan for the prevention of restenosis after stenting of type B2/C lesions: the Val-PREST trial. J Invasive Cardiol. 2001;13:93–7.PubMed

33.

Wakeyama T, Ogawa H, Iida H, et al. Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J. 2003;67:519–22.PubMedCrossRef

34.

Yoshida O, Hirayama H, Nanasato M, et al. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J. 2005;149:e2.PubMedCrossRef

35.

Iwata A, Miura S, Imazumi S, et al. Valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J. 2007;71:31–8.CrossRef

Titel: Inhibition of Atherosclerosis by Angiotensin II Type 1 Receptor Antagonists
verfasst von: Stefan Peters
Publikationsdatum: 01.08.2013
Verlag: Springer International Publishing
Erschienen in: American Journal of Cardiovascular Drugs / Ausgabe 4/2013
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-013-0017-4

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Adherence and Persistence with Prasugrel Following Acute Coronary Syndrome with Percutaneous Coronary Intervention

Lomitapide: A Review of its Use in Adults with Homozygous Familial Hypercholesterolemia

Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents

Clinical Outcomes, Health Resource Use, and Cost in Patients with Early versus Late Dual or Triple Anti-Platelet Treatment for Acute Coronary Syndrome